TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens
The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and pancreatic settings where immuno-oncology has shown moderate efficacy or less.
You may also be interested in...
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
The certainty that any COVID-19 vaccine will see demand outstrip supply could be an inflection point for the once-quiet field of novel vaccine adjuvant research, which promises to enhance immune response and lower the vaccine dose required.